RIC Leadership
The REMS Industry Consortium is led by a Board of Directors including the six founding companies. These are forward-looking organizations committed to coalescing the REMS professional community in the service of patient safety and REMS innovation.
RIC Board of Directors
Kevin Holman, MBA, RAC, RIC Board Member & Chairperson
Johnson & Johnson Innovative Medicine
Kevin Holman, MBA, RAC, leads the REMS & Risk Management Center of Excellence at Johnson & Johnson Innovative Medicine, where he built and leads a team of risk management experts to oversee the design, implementation, management, and assessment of risk management programs in the U.S. and North America. Throughout his career, Kevin has contributed to nearly half of the currently approved shared REMS programs and dozens of single-product REMS programs across various therapeutic areas. Kevin holds a Master of Business Administration degree from Webster University, a Bachelor of Science degree in Biological Sciences from Southern Illinois University ‒ Edwardsville, and a Regulatory Affairs Certification (US-RAC) from the Regulatory Affairs Professional Society.
Carmit Strauss, Pharm.D, RIC Board Member & Vice Chairperson
Takeda
Carmit Strauss, Pharm.D, is Head of Risk Management, Organ Toxicity and Benefit Risk at Takeda. She has extensive experience in risk management, working in various leadership roles within Safety and Pharmacovigilance and Medical Affairs.
Carmit has a broad range of experience in risk management and benefit risk assessment planning, risk minimization and REMS design, implementation and evaluation. Her expertise also includes risk communication and patient-centered approaches and methodologies. In her current role, Carmit provides leadership and subject matter expertise in Risk Management, Benefit/Risk assessment, and Organ Toxicity, and ensures identification and mitigation processes are continuously improved to reflect regulatory trends/guidelines and best practices.
Carmit has been actively collaborating with various cross-industry groups and projects and is a member of the CIOMS XII working group on Benefit-Risk Balance for Medicinal Products. Carmit has authored multiple scientific and benefit risk and risk management abstracts and publications as well as presented at different benefit risk related conferences on various topics.
Carmit obtained her Pharm.D at the University of Southern California (USC) and holds a Bachelor of Science degree in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles (UCLA). Carmit completed her industry post-Doctoral fellowship at Baxter Bioscience.
Cherie Johnson, RIC Board Member and Secretary
Jazz Pharmaceuticals
Cherie Johnson, is the Sr Director, REMS Strategy & Operations at Jazz Pharmaceuticals. Cherie has over 25 years in the industry at Jazz Pharmaceuticals and Orphan Medical, with a specific focus on risk management programs and REMS oxybate products with Jazz Pharmaceuticals and Orphan Medical. At Orphan Medical, Cherie helped develop, implement, and manage a risk management program required for oxybate in the U.S., and led the development of the Patient Services department. Cherie continued her career and role with Jazz Pharmaceuticals, leading Patient Services and managing day-to-day operations with the oxybate risk management program for over 10 years, and then transitioned to a role in REMS with specific responsibilities that include the ongoing REMS development, implementation, operations, compliance, and oversight of Jazz REMS programs.
Tina Latch, RIC Board Member & Treasurer
Endo Pharmaceuticals
Tina Latch, has an extensive background in pharmacovigilance and risk management, and has been a pivotal figure at Endo since 2009. As the Senior Director, she oversees the company's U.S. REMS programs for both branded and generic products. She has 25+ years of experience in the biopharmaceutical industry, encompassing a broad range of expertise, including medical affairs, clinical research, pharmacovigilance, and risk management. Prior to Endo, Tina was at Johnson & Johnson, for ten years in Clinical Data Management, bringing new therapeutic products to market. She has been involved in the development and implementation of numerous shared Risk Evaluation and Mitigation Strategy programs. These programs include those for Alosetron, Alvimopan, Ambrisentan, Mycophenolate, Opioids, Vigabatrin, as well as others. Her leadership continues to guide the strategic direction of Endo's REMS portfolio, ensuring patient safety and regulatory compliance. Tina holds a Bachelor of Science in Nursing degree from the University of Delaware.
Aysha Amman, Pharm.D, RIC Board Member
Amneal
Aysha Amman is a senior Pharmacovigilance leader with 15+ years of pharmaceutical industry experience and strategic oversight of Global Pharmacovigilance Operations, PV Compliance, and REMS Operations. She has extensive expertise in REMS and Risk Management Programs, regulatory compliance, safety governance, signal management, vendor oversight, audits, inspections, and safety systems. Aysha is recognized for building effective governance frameworks, strengthening compliance, leading global teams, and driving process transformation and operational excellence. She brings a strong cross-functional and risk-based approach to REMS and patient safety, with a focus on developing efficient, sustainable, and cost-effective global programs.
Kishore Gopu, MS, MBA, RIC Board Member
Teva Pharmaceuticals
Kishore Gopu, M.S., MBA, Senior Director, REMS Operations, has been with Teva since 2007 and has served in many departments including Regulatory Affairs, Commercial Operations, Patient Solutions, Market Access, and Pharmacovigilance. Since joining Teva, Kishore has built the REMS department from the ground up and has been leading it for the last nine years. Prior to Teva, he worked/consulted for many large corporations, including Wyeth and Johnson & Johnson, for six years. He was involved in the development and implementation of over a half dozen shared REMS programs, including the iPLEDGE®, TIRF REMS, Opioid REMS, and Clozapine REMS, to name a few, and continues to be responsible for the oversight of Teva’s REMS portfolio. Kishore holds an M.S. from the University of South Carolina and an MBA from Fairleigh Dickinson University.
Ron Selders, RIC Board Member
Viatris
Ron Selders, R.Ph., Pharm.D., MBA, Senior Director, has been with Viatris (formerly Mylan) for over 25 years and is currently leading the Product Safety and Risk Management department for the Americas region. Throughout his career, Ron has developed expertise covering a wide-ranging product portfolio in areas such as pharmacovigilance operations, safety surveillance, governance/compliance, audits, and inspections. He also has experience with pharmacovigilance-related company and product integration activities. Ron holds a Bachelor of Science degree in Pharmacy and a Master's in Business Administration degree from West Virginia University, as well as a Doctor of Pharmacy degree from the University of Colorado.
Michele Coiro, MBA RIC Board Member
Bristol Myers Squibb
Michele Coiro is a Senior Director and Head of REMS Strategy at Bristol Myers Squibb, where she brings over a decade of dedicated expertise in Risk Evaluation and Mitigation Strategies. In her role, Michele oversees a broad portfolio of single and shared system REMS programs, serving as a key bridge between operational execution and regulatory strategy. She has been instrumental in the development and implementation of multiple new REMS programs, guiding them from inception through full operational launch. Her deep integration of operational and regulatory expertise has driven compliant, patient-centered REMS administration at BMS, including the administration of shared REMS programs requiring close coordination across multiple industry sponsors. Known for her collaborative leadership style, Michele is committed to driving industry-wide best practices and fostering alignment across stakeholders to support patient safety and appropriate access to critical therapies.
Reema Mehta
Pfizer, Inc.